Preliminary Evidence That ODSH (2-O, 3-O Desulfated Heparin) Is Safe and Enhances Count Recovery in Patients Treated with Intensive Therapy for Acute Myeloid Leukemia – Results of a Pilot Study
Tibor Kovacsovics(Hôpital Edouard Herriot), Paul J. Shami(University of Utah), Linda M. Bavisotto, Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Jeremy Pantin(National Institutes of Health), Kenneth M. Boucher(University of Utah), Thomas P. Kennedy(Wake Forest University), Michael W. Deininger(Versiti Blood Center of Wisconsin), Stephen Marcus(Fort Worth Library), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Cited by 1
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|619
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547
Spectrum of Epithelial Neoplasms in End-Stage Renal Disease
|The American Journal of Surgical Pathology|2006|484